Combination chemotherapy: treatment of the Ehrlich ascites carcinoma and several drug-resistant sublines with combinations of 6-mercaptopurine and 6-(methylmercapto)purine ribonucleoside.
D000818:Animals; D002247:Carbon Isotopes; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D004357:Drug Synergism; D007274:Injections, Intraperitoneal; D015122:Mercaptopurine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009705:Nucleosides / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D012265:Ribonucleotides / Q000096:biosynthesis; D013866:Thioguanine; D013997:Time Factors
D002247:Carbon Isotopes; D009705:Nucleosides; D012263:Ribonucleosides; D012265:Ribonucleotides; D015122:Mercaptopurine; D013866:Thioguanine